COTY · COTY INC

The thesis

Coty Inc. is cutting debt faster than its earnings are recovering, and the shares at $3.29 now sit above every analyst target cited here. The Q1 FY27 report, estimated for 4 November 2026, and the Consumer Beauty strategic review, due by the end of calendar 2026, settle whether the rebound has earned its level.

Financial net debt was $2,912.1M at 30 June 2026, and reported leverage was 3.4 times net debt to adjusted EBITDA (earnings before interest, taxes, depreciation and amortisation). FY26 adjusted EBITDA fell 22% to $846.9M (Coty Q4 FY26 release, 19 August 2026). Management issued no full-year FY27 outlook and called the year a transition year.

The shares closed at $3.29 on 27 October 2026, against $2.94 on 14 October 2026 and $2.65 on 1 October 2026. The narrative is maturing: the turnaround story is well known, and the company items since 14 October 2026 (a partnership with Brandlight on AI-search brand visibility on 27 October 2026, a sustainability update on 21 October 2026) do not touch earnings or debt.

Bullish and bearish views on COTY INC

The bull case on COTY INC (COTY), in brief: Cash generation is improving. The bear case: Earnings are falling faster than debt.

Bull case

• Cash generation is improving. FY26 free cash flow was $348.2M, up from $277.6M a year earlier (Coty release, 19 August 2026). Management guided H1 FY27 free cash flow above $300M.
• Debt is falling. Net debt was $2,912.1M and total debt $3,088.2M at 30 June 2026, against about $3.75B of net debt at the end of FY25 (Coty release, 19 August 2026).
• The Gucci exit brings cash. Coty agreed on 7 July 2026 to return the Gucci beauty licence to Kering for about $400M, with $250M received at signing and $150M due by 30 September 2027.
• The Consumer Beauty review is a large lever. It covers the roughly $1.2B mass colour cosmetics business and the Brazil business of close to $400M in revenue (Coty announcement, 29 September 2025). A named buyer would cut debt further.
• Sector demand is holding. L'Oréal reported Q3 sales of €11.56B against a €11.23B estimate on 22 October 2026, with e-commerce up about 17%.

Bear case

• Earnings are falling faster than debt. FY26 adjusted EBITDA of $846.9M was down 22%, and net revenues of $5,806.6M fell 5% like-for-like (Coty release, 19 August 2026). Q4 adjusted EPS was -$0.02 against a -$0.01 consensus.
• Q1 guidance is weak. Coty guided Q1 adjusted EPS to $0.11-$0.13, below the 14 cents LSEG analyst estimate, and a low-to-mid single-digit like-for-like revenue decline. It also expects adjusted EBITDA to fall by a low-teens percentage (Reuters, 19 August 2026).
• Leadership is unsettled. Markus Strobel has been Executive Chairman and interim CEO since 2 July 2026, and Soraya Benchikh became CFO on 1 September 2026. No permanent CEO has been named.
• The Gucci step-down is ahead. Management said on 19 August 2026 that FY28 sales and profit fall once the licence ends.
• Targets sit below the price. Citigroup's target is $3 at Neutral (14 October 2026), RBC's is $3 at Sector Perform (cut from $8 on 20 August 2026), Morgan Stanley's is $2.75 at Equal-Weight (25 August 2026) and Goldman Sachs's is $2.60 at Neutral (15 August 2026). The $3.29 close is above all four.

Price setup

The shares closed at $3.29 on 27 October 2026, 19.8% below the 52-week high of $4.10. The three-month price change is 22.3%. The 14-day relative strength index (RSI) is 77.5, a reading that normally marks a short-term overbought stretch.

The October rebound ran from $2.43 on 18 September 2026 through $2.65 on 1 October 2026 and $2.94 on 14 October 2026. The only dated analyst item in that stretch is Citigroup's raised target, and the new company items are not about earnings or leverage.

Crowding evidence is mixed. Short interest was 43.25M shares, 4.91% of 880.69M shares outstanding, in the 4 September 2026 snapshot. The Q1 report, estimated for 4 November 2026, is about a week away, and the price has moved past the analyst targets ahead of it.

Catalysts, next 30 days

• ~31 December 2026, est.: Consumer Beauty review deadline. A named buyer or structure for the mass colour and Brazil businesses is the largest remaining de-levering event. It falls outside the 30-day window but decides the case.
• 30 June 2027: Gucci licence ends. The remaining proceeds arrive ahead of the FY28 step-down.

Elapsed catalysts

• ~4 November 2026, est.: Q1 FY27 results. The report tests the $0.11-$0.13 adjusted EPS guide, the low-teens EBITDA decline, and the next reading of net debt and leverage after 3.4x. Coty has not confirmed the date in any source found. (passed 2d ago)

What would change the view

The case breaks if the Q1 FY27 report shows leverage at or above 3.4x despite the Gucci proceeds, or if the review reaches 31 December 2026 with no buyer, structure or timeline. An FY27 adjusted EBITDA range below the FY26 $846.9M would also show earnings still falling faster than debt.

The price condition is a daily close below $2.65, the 1 October 2026 close that preceded the October rebound. A close under that level would return the shares to where they traded before the Citigroup target increase.

What it trades with

Coty trades with beauty and personal-care peers, so the L'Oréal Q3 report on 22 October 2026 was a sector read. Its own drivers dominate: the review outcome, leverage and the CEO search. Fragrance and prestige beauty demand is the main swing factor in the Q1 revenue guide.